Arvinas (NASDAQ:ARVN) reported an automatic sale of common stock by Chief Accounting Officer David K. Loomis on February 23, 2026. Loomis sold 1,108 shares at a price of $12.16 per share, a transaction that totaled approximately $13,473. Company disclosures indicate the sale was executed automatically by Arvinas, INC to satisfy tax obligations and was not a discretionary trade by the officer.
After the transaction, Loomis directly holds 29,692 shares of Arvinas common stock. Market data show the equity has climbed 76% over the past six months and is trading at $13.30 at the time of reporting. According to InvestingPro analysis cited by the company, Arvinas appears undervalued at current market levels; subscribers to that service can access detailed Fair Value metrics and five additional ProTips for further context.
Separately, Arvinas disclosed financial results for the fourth quarter of 2025 that fell short of expectations. The company reported earnings per share of -$1.10, versus a consensus forecast of -$0.51, generating a negative surprise of 115.69%. Revenue for the quarter was reported at $9.5 million, considerably below the anticipated $36.92 million and representing a 74.27% shortfall versus forecast.
In response to the company updates and pipeline developments, Wedbush adjusted its price target on Arvinas to $11 from $9 while maintaining a Neutral rating. The firm cited the company’s progress across its pipeline and the fourth-quarter financial results as factors underpinning its decision.
On the clinical front, Arvinas confirmed that data for its LRRK2 degrader, ARV-102, in Parkinson’s disease patients remain on schedule. Those data are planned for presentation at an upcoming international conference in March 2026. The company described these developments as part of its ongoing projects and said they provide investors with additional information about its research programs.
Taken together, the automatic insider sale, the company’s reported fourth-quarter performance, the analyst price-target adjustment, and the timing for ARV-102 data presentation constitute the most recent items of note for Arvinas’ shareholders and market observers.